GPBAR1 and amyotrophic lateral sclerosis: Further delineation of TGR5 molecular agonists and antagonists in the nervous system may shed further light on neuroprotective mechanisms, and modulation of TGR5 signaling may be a potential pathway to counter axonal loss in neurological disorders such as ALS.